Friday, June 01, 2018—Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regar…
Thursday, April 26, 2018—At the American Academy of Neurology (AAN), researchers Heakyung Kim, Jill Meilahn, Chengcheng Liu, Henry G. Chambers, and Rozalina Dimitrova presented results evaluating the …
Wednesday, April 04, 2018—The first patients to complete the phase 2 clinical trial of AMX0035 (Amylyx; Cambridge, MA), a combination of phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA), for a…
Mark B. Bromberg, MD, PhD
March/April 2018—More treatments are available but with largely subclinical effects.
March/April 2018—Lawful Physician-Hastened Death, Hearing Loss and Cognitive Impairment, Extended-Release Amantadine, Fibromyalgia Biomarkers, Phase 3 Trial of Rimegepant for Migraine, A Blood Test for Concussion, and more.
Wednesday, March 21, 2018—As published in today’s issue of the journal Neuron, researchers have identified specific mutations in the kinesin family gene, KIF5A, that cause amyotrophic lateral scl…
Friday, March 16, 2018—Already approved in 51 countries for some immune deficiencies, subcutaneous immune globulin (IG) (Hizentra; King of Prussia, PA) has now been approved by the Food and Drug Adm…
Thursday, March 15, 2018—The results of a phase 2 proof-of concept study of AMO-02, an investigational therapy for childhood-onset myotonic dystrophy type 1 were presented at the Muscular Dystrophy As…
